Article
Menopausal hormone therapy and the risk of breast cancer in women with a pathogenic variant in BRCA1 or BRCA2.
Journal of the National Cancer Institute - 1 May 2026
Kotsopoulos Joanne, Seca Marta, Gronwald Jacek, Huzarski Tomasz, Møller Pål, Kim Raymond H, Singer Christian F, Karlan Beth, Aeilts Amber, Ramón Y Cajal Teresa, Pal Tuya, Eisen Andrea, Bordeleau Louise, Foulkes William D, Tung Nadine, Couch Fergus, Neuhausen Susan L, Zakalik Dana, Cybulski Cezary, Olopade Olufunmilayo, Metcalfe Kelly, Fruscio Robert, Sun Ping, Lubinski Jan, Narod Steven A
Abstract excerpt
BACKGROUND: Women with a pathogenic variant in BRCA1 or BRCA2 are at high risk of developing ovarian cancer, and it is often recommended that they undergo bilateral salpingo-oophorectomy at an early age, resulting in surgical menopause. Menopausal hormone replacement therapy (HRT) is an effective way to mitigate the adverse outcomes of early menopause; however, the safety of menopausal HRT on breast cancer risk...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.